Back to The Leukemia & Lymphoma Society

It’s the time of year again

This is the time of year that brings to mind charity to others. And The Leukemia & Lymphoma Society (LLS) shares that mindset.

We continue to set our sights on someday, when breakthrough treatments will be able to save the lives of all blood cancer patients.

Today, LLS partnerships with companies like Celator Pharmaceuticals are helping accelerate the development of therapies. Celator is conducting clinical trials with a new therapy (CPX-351) to treat patients with secondary acute myelogenous leukemia (AML).

CPX-351 is two drugs packaged in a way to ensure that the most effective ratio gets directly to the leukemia cells. Encouraging results from a Phase 2 trial of secondary AML patients led to LLS's decision to support the current Phase 3 trial. And we need supporters like you to help continue it.

Partnerships like this will deliver treatments for the estimated 1,012,533 people in the US living with a blood cancer. Which is why we would like to honor every person with a donation.

LLS supporters understand how the impact of their generosity brings us closer to cures; cures that are here, not someday, but today.

There are 1,012,533 patients. Donate in honor of one now.

Thank you,

John E. Walter
President & CEO

to comment